1. Vivos Inc. forms a subsidiary in India for RadioGel production. 2. Plans to expand human trials in India for RadioGel. 3. India will be a key manufacturing center for Vivos. 4. Regulatory approvals are being pursued for expanded trials. 5. Commitment to international business signifies long-term growth.
The establishment of a subsidiary in India signals potential expansion and market growth, historically leading to positive stock performance for biomedical companies like Vivos when entering new markets. As seen with companies such as Amgen, international expansion has often spurred stock increases due to increased revenue potential.
The formation of a subsidiary in India directly impacts RDGL's business strategy and future revenue potential, making it highly relevant in the context of stock price movement. The article discusses critical business developments that would likely prompt investor interest.
The long-term strategy will take time to materialize with regulatory approvals and market establishment, akin to other firms that invested years before reaping significant rewards. This gradual rollout can lead to sustained growth in RDGL's stock price over time.
Kennewick, WA, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL)
The Vivos Board granted authorization to form a wholly owned corporate subsidiary in India. Vivos Inc filed for the name of Vivos Scientific India LLP. Vivos is completing the steps remaining to obtain formal approvals from the Indian government.
"This demonstrates our long-term commitment to doing business in India and supports our long-term plan of establishing our first international manufacturing center for RadioGel and IsoPet, for expanding our developmental animal testing, and for commercially treating humans and animals in India."
India is an important region for us, having initiated first in human trials, which we announced in December of 2024. We are actively pursuing DCGI (Drug Controller General of India) approval for additional expanded human trials in India. As we have previously stated, we believe our India trials are supportive of our IDE process with the FDA. Based on feedback from the FDA, as part of our IDE application process, our formal protocol for the next phase of human trials in India will include immediate post treatment PET full- body scans to further validate RadioGel's safety profile.
Michael K. Korenko, Sc.D.
CEO, Vivos Inc.
Email: MKorenko@RadioGel.com
Follow Vivos Inc. on X (Twitter): @VivosIncUSA
Learn more about RadioGel® and IsoPet® at www.VivosInc.com
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, identified by terms such as "will," "expects," "plans," "anticipates," and "intends." These statements involve risks and uncertainties that may cause actual results to differ materially, including challenges in executing business strategies, economic conditions, competition, regulatory changes, delays in clinic certifications, and other factors beyond Vivos Inc.'s control. For a detailed discussion of these risks, refer to the company's filings with the Securities and Exchange Commission.
